var data={"title":"Pathology and pathogenesis of sarcoidosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pathology and pathogenesis of sarcoidosis</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/contributors\" class=\"contributor contributor_credentials\">Andrew Fontenot, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/contributors\" class=\"contributor contributor_credentials\">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/contributors\" class=\"contributor contributor_credentials\">Kevin R Flaherty, MD, MS</a></dd><dd><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/contributors\" class=\"contributor contributor_credentials\">Andrew Nicholson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Mar 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 25, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sarcoidosis is a multisystem disorder of unknown etiology characterized by the accumulation of T lymphocytes, mononuclear phagocytes, and noncaseating granulomas in involved tissues [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/1,2\" class=\"abstract_t\">1,2</a>]. The lungs are affected in approximately 90 percent of patients, and pulmonary disease accounts for the majority of the morbidity and mortality associated with this disease. Other tissues commonly involved include the skin, eyes, and lymph nodes (<a href=\"image.htm?imageKey=PULM%2F76046\" class=\"graphic graphic_table graphicRef76046 \">table 1</a>).</p><p>The pathology and pathogenesis of sarcoidosis will be reviewed here. The pulmonary and extrapulmonary clinical manifestations, diagnosis, and treatment are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of pulmonary sarcoidosis&quot;</a> and <a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis\" class=\"medical medical_review\">&quot;Extrapulmonary manifestations of sarcoidosis&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cardiac-sarcoidosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of cardiac sarcoidosis&quot;</a> and <a href=\"topic.htm?path=cutaneous-manifestations-of-sarcoidosis\" class=\"medical medical_review\">&quot;Cutaneous manifestations of sarcoidosis&quot;</a> and <a href=\"topic.htm?path=gastrointestinal-and-hepatic-sarcoidosis\" class=\"medical medical_review\">&quot;Gastrointestinal and hepatic sarcoidosis&quot;</a> and <a href=\"topic.htm?path=neurologic-sarcoidosis\" class=\"medical medical_review\">&quot;Neurologic sarcoidosis&quot;</a> and <a href=\"topic.htm?path=renal-disease-in-sarcoidosis\" class=\"medical medical_review\">&quot;Renal disease in sarcoidosis&quot;</a> and <a href=\"topic.htm?path=treatment-of-pulmonary-sarcoidosis-initial-therapy-with-glucocorticoids\" class=\"medical medical_review\">&quot;Treatment of pulmonary sarcoidosis: Initial therapy with glucocorticoids&quot;</a> and <a href=\"topic.htm?path=management-of-cutaneous-sarcoidosis\" class=\"medical medical_review\">&quot;Management of cutaneous sarcoidosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sarcoidosis is a multisystem disease that involves the lungs in 90 percent of cases. It has a predilection for the upper lobes of the lung and bronchovascular bundles more than other lung compartments, although it can affect any area [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/3-5\" class=\"abstract_t\">3-5</a>]. Lung involvement is often associated with hilar and mediastinal lymphadenopathy. </p><p>On histopathology, classic sarcoid granulomas are non-necrotizing with a tightly packed central area composed of macrophages, epithelioid cells, multinucleated giant cells, and T lymphocytes that are CD4 positive (<a href=\"image.htm?imageKey=PULM%2F115232\" class=\"graphic graphic_picture graphicRef115232 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/3,5\" class=\"abstract_t\">3,5</a>]. The central areas are surrounded by CD8 and CD4 positive T lymphocytes, B lymphocytes, monocytes, mast cells, and fibroblasts, which in turn are surrounded by lamellar rings of hyaline collagen. The proportions of lymphocytic infiltrate and fibrosis surrounding the granulomas vary depending on the patient and disease duration. Additional histopathologic features of sarcoid granulomas that may be present include asteroid bodies, Schaumann bodies, and birefringent crystalline particles (calcium oxalate and other calcium salts (<a href=\"image.htm?imageKey=PULM%2F83308\" class=\"graphic graphic_picture graphicRef83308 \">picture 2</a> and <a href=\"image.htm?imageKey=PULM%2F83306\" class=\"graphic graphic_picture graphicRef83306 \">picture 3</a> and <a href=\"image.htm?imageKey=PULM%2F83307\" class=\"graphic graphic_picture graphicRef83307 \">picture 4</a>)).</p><p>In rare patients with necrotizing sarcoid granulomatosis, the histopathology shows perivascular masses composed of confluent granulomas and necrosis of lung parenchyma. Features that favor a diagnosis of necrotizing sarcoid granulomatosis include the following [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/6\" class=\"abstract_t\">6</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A background of nonnecrotizing sarcoid granulomas in a lymphangitic distribution</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Negative special stains for fungal and mycobacterial infection</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Negative mycobacterial polymerase chain reaction (PCR) &#160;</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Absence of blood vessel wall fibrinoid necrosis (evaluated by elastin stains) in areas peripheral to the necrotic center</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Negative serum antineutrophil cytoplasmic antibody</p><p/><p class=\"headingAnchor\" id=\"H452678738\"><span class=\"h1\">IMMUNOPATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The steps involved in the formation of sarcoid granulomas involve a complex interplay of immune cells and their mediators. One of the first steps is thought to be the phagocytosis and presentation of an (unidentified) antigen by antigen-presenting cells such as macrophages or dendritic cells [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"#H3\" class=\"local\">'Possible etiologic agents'</a> below.)</p><p>The putative antigen is presented to cluster of differentiation 4 (CD4)+ T helper lymphocytes, which then amplify the immune response through elaboration of interferon-gamma, interleukin (IL)-2 and other cytokines, aided by T regulatory cells (Tregs) that also produce interferon-gamma [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/7-9\" class=\"abstract_t\">7-9</a>]. Increased expression of the transcription factor T-bet and chemokine receptor CXCR3 contribute to a Th1 orientation. </p><p>The sarcoid granuloma can resolve without sequelae, or undergo obliterative fibrosis, with the resultant development of interstitial fibrosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/2,10\" class=\"abstract_t\">2,10</a>]. </p><p class=\"headingAnchor\" id=\"H1205830726\"><span class=\"h2\">Macrophages and dendritic cells</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, formation of a granuloma is initiated by the presence of a foreign antigen, which stimulates monocytes to differentiate into antigen-presenting cells, such as macrophages or dendritic cells. When macrophages aggregate in response to antigen they evolve into epithelioid cells. Further stimulation by inflammatory mediators leads to fusion of macrophages and dendritic cells into multinucleated giant cells. As the granuloma matures, these macrophages, epithelioid cells, and a few multinucleated giant cells form a tight central cluster [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/4,7\" class=\"abstract_t\">4,7</a>]. (See <a href=\"topic.htm?path=antigen-presenting-cells\" class=\"medical medical_review\">&quot;Antigen-presenting cells&quot;</a>.) </p><p>The function of alveolar macrophages as the antigen presenting cell in sarcoidosis is also believed to be relevant to the outcome of disease, promoting either remission or prolonged chronic inflammation in the lungs [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/11\" class=\"abstract_t\">11</a>]. Using a quantitative proteomics approach coupled to mass spectrometry, 25 unique proteins were identified in alveolar macrophages from patients with sarcoidosis. Several of the identified proteins were related to key alveolar macrophage functionality, including the Fc-gamma-mediated phagocytosis and Clathrin-mediated endocytosis pathways. The importance of these findings will require additional study. </p><p>Furthermore, excessive granuloma formation has been described after deletion of the gene encoding tuberous sclerosis 2 (TSC2) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/12\" class=\"abstract_t\">12</a>]. This deletion resulted in activation of the metabolic checkpoint kinase mTORC1 in macrophages. In addition, mTORC1 activation and macrophage proliferation were correlated with clinical disease progression in sarcoidosis patients [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/12\" class=\"abstract_t\">12</a>]. </p><p class=\"headingAnchor\" id=\"H379141950\"><span class=\"h2\">T lymphocytes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>T lymphocytes with cell surface expression of CD4 include subsets of T helper type 1 (Th1), T helper type 2 (Th2), T helper type 17 (Th17), and Treg cells, among others. (See <a href=\"topic.htm?path=t-helper-subsets-differentiation-and-role-in-disease\" class=\"medical medical_review\">&quot;T helper subsets: Differentiation and role in disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3645136627\"><span class=\"h3\">T helper cells</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunohistochemical staining of sarcoid granulomas has demonstrated that the majority of lymphocytes within the granuloma are CD4+ Th1 lymphocytes. However, the periphery of the granuloma is composed of CD4+ as well as CD8+ T cells [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/13,14\" class=\"abstract_t\">13,14</a>]. Since the cells obtained with bronchoalveolar lavage (BAL) in sarcoidosis reflect the degree of alveolitis seen on lung biopsy [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/15,16\" class=\"abstract_t\">15,16</a>], BAL has been used to assess the cellular populations present in the lower respiratory tract.</p><p>Examination of BAL fluid from patients with sarcoidosis typically demonstrates dramatic increases in cellularity [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/2,17,18\" class=\"abstract_t\">2,17,18</a>]. The cell count differential of BAL fluid demonstrates a lymphocytic pleocytosis, with a predominance of CD4+ T cells relative to peripheral blood or lung lymphocytes obtained from healthy controls [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/2,17,18\" class=\"abstract_t\">2,17,18</a>]. These CD4+ T cells bear surface markers of previous activation and have the ability to spontaneously secrete IL-2, interferon-gamma, and other cytokines characteristic of the Th1 phenotype. Thus, CD4+ T cells may be important in initiating and perpetuating the disease process [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/2,17,19-22\" class=\"abstract_t\">2,17,19-22</a>]. (See <a href=\"topic.htm?path=role-of-cytokines-in-the-immune-system#H13\" class=\"medical medical_review\">&quot;Role of cytokines in the immune system&quot;, section on 'T cell subsets'</a>.)</p><p>In comparison to the BAL findings, the peripheral blood of patients with pulmonary sarcoidosis shows a T cell lymphopenia, a decrease in the number of CD4+ T cells, and a decreased ratio of <span class=\"nowrap\">CD4+/CD8+</span> T cells. One study noted that a specific subset of CD4+ T cells with immunoregulatory properties, known as CD1d-restricted natural killer cells (CD1d-rNKT cells), are profoundly decreased or absent in both the peripheral blood and BAL fluid of patients with sarcoidosis, regardless of disease activity [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/23\" class=\"abstract_t\">23</a>]. A decreased in vitro response to T cell mitogens also occurs, and a hypergammaglobulinemia is observed secondary to generalized B cell hyperactivity [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/13\" class=\"abstract_t\">13</a>]. Spontaneous clinical resolution has been shown to coincide with restoration of CD4+ Th1 and Treg cell function, whereas continued T cell anergy is a feature of disease progression [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/24\" class=\"abstract_t\">24</a>].</p><p class=\"headingAnchor\" id=\"H690504389\"><span class=\"h3\">T regulatory cells</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>T regulatory lymphocytes (Tregs, formerly called T suppressor cells) are CD4+, like Th1 lymphocytes, but their role is to downregulate immune response. (See <a href=\"topic.htm?path=normal-b-and-t-lymphocyte-development#H1232172\" class=\"medical medical_review\">&quot;Normal B and T lymphocyte development&quot;, section on 'Regulatory T cells (Tregs)'</a>.)</p><p class=\"headingAnchor\" id=\"H3196799771\"><span class=\"h2\">T cell receptor</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Due to the intimate association between CD4+ T cells and the pathogenesis of sarcoidosis, numerous groups have investigated the T cell antigen receptor (TCR) (<a href=\"image.htm?imageKey=PULM%2F53512\" class=\"graphic graphic_figure graphicRef53512 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/17,20-22,25,26\" class=\"abstract_t\">17,20-22,25,26</a>]. The TCR is composed of an alpha and a beta chain and is responsible for recognizing processed peptide antigens in the context of class I or II MHC [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/27\" class=\"abstract_t\">27</a>]. The enormous diversity of the TCR is acquired through somatic rearrangement of the variable (V), diversity (D), and joining (J) segments along with the random addition <span class=\"nowrap\">and/or</span> deletion of N-region nucleotides to form a unique V(D)J region (<a href=\"image.htm?imageKey=PULM%2F53335\" class=\"graphic graphic_figure graphicRef53335 \">figure 2</a>).</p><p>Studies of the TCR Vbeta repertoire in patients with active sarcoidosis has demonstrated bias in certain TCR Vbeta subsets, including Vbeta2, Vbeta8, Vbeta12, and Valpha2.3 [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/17,20-22,25,26\" class=\"abstract_t\">17,20-22,25,26</a>]. In addition, different Vbeta gene segments are expanded in different individuals. A possible explanation for this observation is that the HLA class II type might select the predominant Vbeta expressed among different patients. Some studies, for example, have found an increased number of Valpha2.3+ T cells in patients with sarcoidosis who express HLA-DR3. Another explanation for the different Vbetas is that different epitopes or antigens are being recognized at the site of disease activity.</p><p>Junctional region sequencing has demonstrated that the preferential expression of specific Vbeta regions in the BAL is oligoclonal in nature, suggesting conventional antigenic (Ag) stimulation [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/17,20-22\" class=\"abstract_t\">17,20-22</a>]. This is in contrast with superantigenic stimulation, which results in polyclonal expansion of a particular Vbeta gene segment [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/28\" class=\"abstract_t\">28</a>]. Interestingly, the Kveim reaction site is also characterized by a limited TCR Vbeta repertoire consistent with an Ag-driven immune response [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/21\" class=\"abstract_t\">21</a>]. Taken together, these observations suggest that the activated, disease-specific CD4+ T cell clones accumulate at sites of disease activity in response to unknown sarcoid antigen(s).</p><p class=\"headingAnchor\" id=\"H1983033123\"><span class=\"h2\">Cytokines</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The granulomatous response in sarcoidosis is characterized by a highly-polarized Th1 cytokine response. After T cell recognition of antigen(s), CD4+ T cells secrete Th1-type cytokines such as IL-2, interferon (IFN) gamma, and tumor necrosis factor (TNF) alpha. The release of IFN gamma and TNF alpha promotes macrophage accumulation, activation, and aggregation, resulting in the development of granulomatous inflammation (<a href=\"image.htm?imageKey=ALLRG%2F78712\" class=\"graphic graphic_figure graphicRef78712 \">figure 3</a>) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=role-of-cytokines-in-the-immune-system\" class=\"medical medical_review\">&quot;Role of cytokines in the immune system&quot;</a> and <a href=\"topic.htm?path=t-helper-subsets-differentiation-and-role-in-disease#H6\" class=\"medical medical_review\">&quot;T helper subsets: Differentiation and role in disease&quot;, section on 'Cytokine profiles'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Interleukins-2 and 15</strong> &ndash; IL-2 is important in expanding the activated lymphocyte population within the lung, either by in situ proliferation or by cellular redistribution from the peripheral blood [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/13\" class=\"abstract_t\">13</a>]. In addition, IL-2 is involved in the differentiation of B cells with the resultant development of hypergammaglobulinemia. Activated CD4+ T cells possess IL-2 receptors and have the ability to proliferate in vitro in the presence of IL-2 [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/17\" class=\"abstract_t\">17</a>]. IL-15 is produced by macrophages and cooperates with IL-2 in initiating cell-mediated immune responses [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/30\" class=\"abstract_t\">30</a>]. IL-15 shares several biologic functions with IL-2, including stimulating the proliferation of T cells and B cells. Even though IL-15 and IL-2 are structurally dissimilar, the effects of IL-15 occur through the IL-2 receptor system and may trigger the proliferation of CD4+ T cells in sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/30\" class=\"abstract_t\">30</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Stimulation of interferon-gamma</strong> &ndash; Several cytokines (eg, IL-12, IL-18, and IL-27) promote Th1 immune responses and are increased in the lungs of sarcoidosis patients [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/31-33\" class=\"abstract_t\">31-33</a>]. These cytokines act synergistically to stimulate IFN-gamma production from CD4+ Th1 cells. In addition, Th17 cells, which have been identified in blood and BAL fluid of patients with active sarcoidosis, secrete interferon-gamma and may play a role in the alveolitis phase of disease, potentially leading to fibrosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/9,18\" class=\"abstract_t\">9,18</a>]. IL-17A&ndash;secreting cells have been found in BAL from patients with sarcoidosis. </p><p/><p class=\"bulletIndent1\">In addition, a marked expansion of Th17.1 cells that only produce IFN-gamma has been identified [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/9,34\" class=\"abstract_t\">9,34</a>]. These findings suggest that Th17.1 cells may be the predominant producer of IFN-gamma in pulmonary sarcoidosis, but raise concerns about possible misclassification of Th17.1 cells as Th1 cells [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/9\" class=\"abstract_t\">9</a>].</p><p/><p class=\"bulletIndent1\">Upregulation of genes related to Type I and II interferon signaling pathways has been identified in the blood and BAL fluid of patients with sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/35\" class=\"abstract_t\">35</a>]. In addition, interferon-gamma-inducible chemokines, CXCL9 and CXCL10, are elevated in the serum of sarcoidosis subjects compared with controls. The levels of these chemokines correlate with the lung function measurements (eg, diffusing capacity for carbon monoxide [DLCO] and forced vital capacity [FVC]) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/36-38\" class=\"abstract_t\">36-38</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Interleukins 6 and 8</strong> &ndash; Elevated levels of IL-6 and IL-8 have been identified in the BAL fluid of patients with active pulmonary sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/39,40\" class=\"abstract_t\">39,40</a>]. IL-6 is produced by macrophages, fibroblasts, and T and B cells, and is a signal for T and B cell proliferation. IL-8 is a potent neutrophil chemotactic factor released from macrophages. A positive correlation existed between IL-6 and IL-8 levels in the BAL fluid and BAL neutrophilia [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/39\" class=\"abstract_t\">39</a>]. An association has previously been noted between BAL neutrophilia and a worse prognosis in sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/40\" class=\"abstract_t\">40</a>]. Thus, IL-6 and IL-8 may be important in modifying the disease process.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Shift to Th2 profile</strong> &ndash; In some patients, the Th1 type profile shifts to a Th2 type profile with the release of Th2 cytokines, such as IL-4, which stimulates the production of extracellular matrix proteins, acts as a chemoattractant for fibroblasts, and contributes to the evolution of lung fibrosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/13\" class=\"abstract_t\">13</a>]. </p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">POSSIBLE ETIOLOGIC AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Despite advances in our knowledge of the immunopathogenesis of sarcoidosis, the exact stimulus that initiates the disease process remains elusive. The presence of granulomatous inflammation is thought to result from an exaggerated cell-mediated immune response to one or more unidentified antigen(s) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/2,13,41\" class=\"abstract_t\">2,13,41</a>]. The multicenter National Institutes of Health (NIH)-funded ACCESS case-control study of over 700 patients and nearly 30,000 relatives found no single etiologic agent and no genetic locus was clearly implicated in the pathogenesis of sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/42-44\" class=\"abstract_t\">42-44</a>]. Several possible associations have been investigated, as outlined below.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Occupational and environmental exposures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Certain occupational exposures, such as beryllium [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/45\" class=\"abstract_t\">45</a>], zirconium [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/46,47\" class=\"abstract_t\">46,47</a>], and aluminum [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/48\" class=\"abstract_t\">48</a>], are associated with development of granulomas that are similar to sarcoid granulomas. These associations have raised the possibility that other occupational or environmental exposures might be etiologic in sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/49-51\" class=\"abstract_t\">49-51</a>]. </p><p>A case series suggested that exposure to World Trade Center (WTC) dust during the collapse, rescue, or recovery was associated with an increased incidence of sarcoidosis-like granulomatous pulmonary disease during the five years following the disaster [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/49\" class=\"abstract_t\">49</a>]. The series reported 26 patients who had pathologic evidence of new onset sarcoidosis following WTC dust exposure. The estimated annual incidence rate was 86 cases per 100,000 population during the first year after the WTC collapse and 22 cases per 100,000 population during the next four years. In comparison, the estimated annual incidence rate was 15 cases per 100,000 during the 15 years prior to the disaster. Eighteen of the 26 patients (69 percent) also developed findings consistent with asthma. Further, an elevated risk of sarcoidosis-like granulomatous pulmonary disease was not limited to the year immediately after the disaster among people who performed intensive rescue and recovery work [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/50\" class=\"abstract_t\">50</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Infectious agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Numerous microorganisms, most notably mycobacteria and cutibacteria (formerly propionibacteria), have been implicated as possible etiologic agents of sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/51-66\" class=\"abstract_t\">51-66</a>]. In addition, the apparent transmission of sarcoidosis following lung, cardiac and bone marrow transplantation has also provided support for an infectious etiologic agent [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/67-71\" class=\"abstract_t\">67-71</a>]. </p><p>The histologic similarity of sarcoidosis to <em>Mycobacterium tuberculosis</em> infection led to the extensive evaluation of this organism as a possible etiologic factor [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/52,64\" class=\"abstract_t\">52,64</a>]. A number of studies, including those using hybridization techniques and the polymerase chain reaction, found evidence of <em>M. tuberculosis</em> in sarcoid tissue [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/53,54\" class=\"abstract_t\">53,54</a>]; however, these findings have not been confirmed in other reports using similar techniques [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/55-59\" class=\"abstract_t\">55-59</a>].</p><p>One intriguing study demonstrated growth of acid-fast cell-wall-deficient forms of bacteria (L forms) from the blood of 19 of 20 patients with sarcoidosis but none of 20 controls [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/60\" class=\"abstract_t\">60</a>]. However, a large case-control study found no difference in the number of cell wall-deficient mycobacterial forms in blood cultures from patients with and without sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/61\" class=\"abstract_t\">61</a>].</p><p>A mycobacterial antigen, <em>M. tuberculosis</em> catalase-peroxidase (mKatG), was found in most sarcoidosis tissue samples examined, but not in control tissues [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/72\" class=\"abstract_t\">72</a>]. In a related study, an increased number of T cells reactive to mKatG were found in peripheral blood and bronchoalveolar lavage (BAL) fluid from patients with sarcoidosis, compared with healthy controls [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/73\" class=\"abstract_t\">73</a>]. In sarcoidosis, the mKatG-reactive T cells preferentially accumulated in the lung, indicating a compartmentalized response and are consistent with the profile expected for a pathogenic antigen.</p><p>A study from Japan reported detection of <em>Propionibacterium acnes</em> (now <em>Cutibacterium acnes</em>) in lymph nodes from 12 of 15 patients with sarcoidosis using the polymerase chain reaction; positive results, but with many fewer genome copies, were also found in 2 of 15 patients with tuberculosis and in 3 of 15 controls [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/59\" class=\"abstract_t\">59</a>]. All three patients with sarcoidosis who did not have detectable <em>P. acnes</em> did have another species of cutibacteria (<em>Propionibacterium granulosum</em>, now <em>Cutibacterium granulosum</em>) found by the polymerase chain reaction. Cutibacteria may act to &quot;prime&quot; the immune system prior to the development of sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/74\" class=\"abstract_t\">74</a>]. Although this theory is intriguing, it is not yet known whether there is any causal relationship between cutibacteria and sarcoidosis. (See <a href=\"topic.htm?path=invasive-cutibacterium-formerly-propionibacterium-infections\" class=\"medical medical_review\">&quot;Invasive Cutibacterium (formerly Propionibacterium) infections&quot;</a>.)</p><p>While human herpes virus (HHV)-8 DNA sequences were detected in lung biopsies in eight of eight sarcoid patients compared with 3 of 56 controls [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/75\" class=\"abstract_t\">75</a>] in one study, subsequent studies have not confirmed these findings [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/76,77\" class=\"abstract_t\">76,77</a>]. High titers of antibodies against a number of lymphotropic viruses (eg, HHV6, HHV8, HIV, HTLV1, cytomegalovirus) have been observed in patients with sarcoid, but it seems likely that this reflects generalized B cell activation rather than being indicative of an etiology [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/51\" class=\"abstract_t\">51</a>].</p><p class=\"headingAnchor\" id=\"H2269876926\"><span class=\"h2\">Kveim-Siltzbach reagent</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 70 percent of patients with early sarcoidosis develop granulomatous inflammation identical to sarcoidosis four to six weeks after the intradermal injection of the Kveim-Siltzbach reagent (consisting of homogenates of human sarcoid tissue) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/78\" class=\"abstract_t\">78</a>]. Vimentin is a type III filament protein that is part of the cytoskeleton of human mesenchymal cells and bacteria and a component of the Kveim-Siltzbach reagent. </p><p>While multiple previous studies of the components of the Kveim-Siltzbach reagent failed to identify a responsible antigen, one study used mass spectrometry to identify proteins in the Kveim reagent [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/79\" class=\"abstract_t\">79</a>]. Three potential protein candidates (vimentin, tubulin, and alpha-actinin-4) were selected. Peripheral blood mononuclear cells (PBMCs) from sarcoidosis patients and healthy individuals were exposed to the three candidate proteins and the reactions compared with those to Kveim reagent. Kveim reagent and vimentin induced similar patterns of cytokine secretion by sarcoidosis PBMCs, which were different from healthy PBMCs.</p><p class=\"headingAnchor\" id=\"H2219860226\"><span class=\"h2\">Potential role for vimentin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vimentin has also been implicated as an antigenic factor causing clonal expansion of CD4+ T lymphocytes carrying the T cell receptor Valpha2.3<sup>+</sup>Vbeta22<sup>+</sup> in patients with L&ouml;fgren syndrome [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/7,80\" class=\"abstract_t\">7,80</a>]. Molecular modelling suggests that a vimentin-derived protein fits into the HLA binding cleft of a specific T cell receptor (HLA-DRB1*03) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/80\" class=\"abstract_t\">80</a>].</p><p class=\"headingAnchor\" id=\"H2358848511\"><span class=\"h2\">Serum amyloid A</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Serum amyloid A (SAA) is an acute phase protein that participates in the inflammatory response in sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/81-83\" class=\"abstract_t\">81-83</a>]. Increased SAA levels have been noted in serum from patients with sarcoidosis and correlate with measures of disease burden [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/81\" class=\"abstract_t\">81</a>]. In a study of SAA staining of samples from patients with sarcoid and nonsarcoid granulomas, SAA staining was 84 percent specific for sarcoid granulomas, but 44 percent sensitive [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/83\" class=\"abstract_t\">83</a>].</p><p class=\"headingAnchor\" id=\"H575707723\"><span class=\"h1\">GENETIC PREDISPOSITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The occasional occurrence of sarcoidosis in more than one member of a family suggests the possibility of a genetic contribution [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/84-88\" class=\"abstract_t\">84-88</a>]. An ambitious case-control study of 706 patients and over 27,000 first- and second-degree relatives confirmed that first-degree relatives are at increased risk for developing sarcoidosis (odds ratio [OR] 4.7, 95% CI 2.3-9.7) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/42\" class=\"abstract_t\">42</a>]. This risk was greater for relatives of Caucasian patients than for those of African-American descent (OR 18 versus 2.8).</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Major histocompatibility complex</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Genetic susceptibility to sarcoidosis has been most closely linked with antigens of the major histocompatibility complex (MHC) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/29,89\" class=\"abstract_t\">29,89</a>]. However, the pattern varies depending upon the ethnic and racial makeup of the population studied, and the associations are relatively weak [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/90-93\" class=\"abstract_t\">90-93</a>]. In ACCESS, the HLA-DR allele, <em>DRB1*1101</em>, was significantly associated with sarcoidosis development in both African-Americans and Caucasians [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/94\" class=\"abstract_t\">94</a>]. This study and others suggest that the genetic background of the individual may account for the clinical heterogeneity of sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/93,95\" class=\"abstract_t\">93,95</a>]. For example, in Scandinavian subjects with acute sarcoidosis (L&ouml;fgren's syndrome) and other white populations with sarcoidosis, an association between the presence of <em>HLA-DRB1*0301</em> and remitting sarcoidosis has been described [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/96\" class=\"abstract_t\">96</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Other genes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Genome wide linkage and association studies have identified some additional genes that may be associated with increased susceptibility to sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/97-101\" class=\"abstract_t\">97-101</a>]. These include the butyrophilin-like 2 gene (BTNL2) and annexin A11 (ANXA11) [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/88,102-104\" class=\"abstract_t\">88,102-104</a>]. Other studies have suggested an association between the presence <span class=\"nowrap\">and/or</span> severity of sarcoidosis and angiotensin converting enzyme variants in certain subgroups of patients, including African-Americans and Finns [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/105,106\" class=\"abstract_t\">105,106</a>].</p><p>Gene expression analysis has been used to identify networks of genes that may be involved in sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/107,108\" class=\"abstract_t\">107,108</a>]. As an example, gene array studies on lung tissue from healthy controls and patients with active sarcoidosis identified over-expression of two gene networks [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/107\" class=\"abstract_t\">107</a>]. One network includes genes associated with T helper 1 (Th1) type antigen responses (ie, interleukin [IL]-7, IL-15, the transcription factor family STAT1, and lymphocyte chemoattractant genes); the second network includes the proteases MMP-12 and ADAMDEC1. It is thought that these proteases participate in lung remodeling, although their exact role is not known.</p><p>Lung gene expression profiles have been compared between patients with nodular self-limiting sarcoidosis and those with progressive fibrotic pulmonary sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/108\" class=\"abstract_t\">108</a>]. A greater number of up-regulated genes than down-regulated genes were noted in patients with progressive fibrotic disease, compared with self-limiting disease. In a separate study using whole genome expression profiles in a cohort of sarcoidosis patients, an unbiased gene signature comprised of 20 autosomal genes was identified that appears to distinguish patients with complicated sarcoidosis from patients with uncomplicated sarcoidosis [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/109\" class=\"abstract_t\">109</a>]. </p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">OTHER ASSOCIATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Non-necrotizing granulomas are seen in some patients with common variable immunodeficiency (CVID), which may provide some insight into the pathogenesis of sarcoid granulomas. </p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Granulomatous and lymphocytic interstitial lung disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Granulomatous and lymphocytic interstitial lung disease (GLILD) has been reported in patients with CVID and other primary immunodeficiency diseases. GLILD is characterized by non-necrotizing (sarcoid-like) granulomas, lymphoid interstitial pneumonia, and follicular bronchiolitis on lung biopsy. The clinical features of GLILD are discussed separately. (See <a href=\"topic.htm?path=pulmonary-complications-of-primary-immunodeficiencies#H123667652\" class=\"medical medical_review\">&quot;Pulmonary complications of primary immunodeficiencies&quot;, section on 'Granulomatous and lymphocytic interstitial lung disease'</a>.) </p><p>Like sarcoidosis, GLILD is often accompanied by hilar and mediastinal lymphadenopathy [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/110\" class=\"abstract_t\">110</a>]. However, sarcoidosis has a number of features that distinguish it from GLILD, including normal or elevated serum immunoglobulin levels and frequent spontaneous remissions. An association between herpes virus 8 (HHV8) and GLILD has been noted, suggesting a possible relationship between HHV8 infection and granuloma formation in predisposed individuals [<a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/111\" class=\"abstract_t\">111</a>]. </p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=sarcoidosis-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Sarcoidosis (The Basics)&quot;</a>)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=sarcoidosis-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Sarcoidosis (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sarcoidosis is a multisystem disorder of unknown etiology. Approximately 90 percent of patients with sarcoidosis have lung involvement. Sarcoidosis has a predilection for the upper lung zones and bronchovascular bundles, but can affect any area of the lung. Lung involvement is often associated with hilar and mediastinal lymphadenopathy. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above and <a href=\"#H2\" class=\"local\">'Pathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Classic sarcoid granulomas are non-necrotizing with a tightly packed central area composed of macrophages, epithelioid cells, multinucleated giant cells, and T lymphocytes that are CD4 positive. This central area is surrounded by a mixture CD8 and CD4 positive T lymphocytes, B lymphocytes, monocytes, mast cells, and fibroblasts, which in turn are surrounded by lamellar rings of hyaline collagen. (See <a href=\"#H2\" class=\"local\">'Pathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The steps involved in the formation of sarcoid granulomas involve a complex interplay of immune cells, including macrophages, dendritic cells, T helper lymphocytes, T regulatory cells (Tregs), and their mediators. (See <a href=\"#H452678738\" class=\"local\">'Immunopathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>While studies of the T cell antigen receptor (TCR) Vbeta repertoire suggest conventional antigenic stimulation, the exact etiologic agent(s) remain a mystery. Potential culprits include occupational and environmental exposures, infectious agents (eg, components of mycobacteria or cutibacteria), Kveim-Siltzbach reagent, and vimentin. (See <a href=\"#H3\" class=\"local\">'Possible etiologic agents'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The occasional occurrence of sarcoidosis in more than one member of a family suggests the possibility of a genetic contribution. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Genetic susceptibility has been most closely linked with antigens of the major histocompatibility complex (MHC), although the associations vary depending on racial and ethnic factors. (See <a href=\"#H7\" class=\"local\">'Major histocompatibility complex'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Genome wide linkage and association studies have identified genes that may be associated with increased susceptibility to sarcoidosis, such as butyrophilin-like 2 gene (BTNL2), annexin A11 (ANXA11), and angiotensin converting enzyme variants, although the associations vary across populations. (See <a href=\"#H8\" class=\"local\">'Other genes'</a> above.)</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/1\" class=\"nounderline abstract_t\">Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/2\" class=\"nounderline abstract_t\">Thomas PD, Hunninghake GW. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 1987; 135:747.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/3\" class=\"nounderline abstract_t\">Soler P, Basset F. Morphology and distribution of the cells of a sarcoid granuloma: ultrastructural study of serial sections. Ann N Y Acad Sci 1976; 278:147.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/4\" class=\"nounderline abstract_t\">Rossi G, Cavazza A, Colby TV. Pathology of Sarcoidosis. Clin Rev Allergy Immunol 2015; 49:36.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/5\" class=\"nounderline abstract_t\">Ma Y, Gal A, Koss MN. The pathology of pulmonary sarcoidosis: update. Semin Diagn Pathol 2007; 24:150.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/6\" class=\"nounderline abstract_t\">Mukhopadhyay S, Wilcox BE, Myers JL, et al. Pulmonary necrotizing granulomas of unknown cause: clinical and pathologic analysis of 131 patients with completely resected nodules. Chest 2013; 144:813.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/7\" class=\"nounderline abstract_t\">Sakthivel P, Bruder D. Mechanism of granuloma formation in sarcoidosis. Curr Opin Hematol 2017; 24:59.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/8\" class=\"nounderline abstract_t\">Broos CE, Hendriks RW, Kool M. T-cell immunology in sarcoidosis: Disruption of a delicate balance between helper and regulatory T-cells. Curr Opin Pulm Med 2016; 22:476.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/9\" class=\"nounderline abstract_t\">Ramstein J, Broos CE, Simpson LJ, et al. IFN-&gamma;-Producing T-Helper 17.1 Cells Are Increased in Sarcoidosis and Are More Prevalent than T-Helper Type 1 Cells. Am J Respir Crit Care Med 2016; 193:1281.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/10\" class=\"nounderline abstract_t\">Mitchell DN, Scadding JG. Sarcoidosis. Am Rev Respir Dis 1974; 110:774.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/11\" class=\"nounderline abstract_t\">Silva E, Souchelnytskyi S, Kasuga K, et al. Quantitative intact proteomics investigations of alveolar macrophages in sarcoidosis. Eur Respir J 2013; 41:1331.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/12\" class=\"nounderline abstract_t\">Linke M, Pham HT, Katholnig K, et al. Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression. Nat Immunol 2017; 18:293.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/13\" class=\"nounderline abstract_t\">Agostini C, Adami F, Semenzato G. New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol 2000; 12:71.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/14\" class=\"nounderline abstract_t\">Semenzato G, Pezzutto A, Chilosi M, Pizzolo G. Redistribution of T lymphocytes in the lymph nodes of patients with sarcoidosis. N Engl J Med 1982; 306:48.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/15\" class=\"nounderline abstract_t\">Semenzato G, Chilosi M, Ossi E, et al. Bronchoalveolar lavage and lung histology. Comparative analysis of inflammatory and immunocompetent cells in patients with sarcoidosis and hypersensitivity pneumonitis. Am Rev Respir Dis 1985; 132:400.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/16\" class=\"nounderline abstract_t\">Campbell DA, Poulter LW, du Bois RM. Immunocompetent cells in bronchoalveolar lavage reflect the cell populations in transbronchial biopsies in pulmonary sarcoidosis. Am Rev Respir Dis 1985; 132:1300.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/17\" class=\"nounderline abstract_t\">Forrester JM, Wang Y, Ricalton N, et al. TCR expression of activated T cell clones in the lungs of patients with pulmonary sarcoidosis. J Immunol 1994; 153:4291.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/18\" class=\"nounderline abstract_t\">Facco M, Cabrelle A, Teramo A, et al. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2011; 66:144.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/19\" class=\"nounderline abstract_t\">NIH conference. Pulmonary sarcoidosis: a disease characterized and perpetuated by activated lung T-lymphocytes. Ann Intern Med 1981; 94:73.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/20\" class=\"nounderline abstract_t\">Forman JD, Klein JT, Silver RF, et al. Selective activation and accumulation of oligoclonal V beta-specific T cells in active pulmonary sarcoidosis. J Clin Invest 1994; 94:1533.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/21\" class=\"nounderline abstract_t\">Klein JT, Horn TD, Forman JD, et al. Selection of oligoclonal V beta-specific T cells in the intradermal response to Kveim-Siltzbach reagent in individuals with sarcoidosis. J Immunol 1995; 154:1450.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/22\" class=\"nounderline abstract_t\">Moller DR, Konishi K, Kirby M, et al. Bias toward use of a specific T cell receptor beta-chain variable region in a subgroup of individuals with sarcoidosis. J Clin Invest 1988; 82:1183.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/23\" class=\"nounderline abstract_t\">Ho LP, Urban BC, Thickett DR, et al. Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. Lancet 2005; 365:1062.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/24\" class=\"nounderline abstract_t\">Oswald-Richter KA, Richmond BW, Braun NA, et al. Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. J Immunol 2013; 190:5446.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/25\" class=\"nounderline abstract_t\">Grunewald J, Olerup O, Persson U, et al. T-cell receptor variable region gene usage by CD4+ and CD8+ T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Proc Natl Acad Sci U S A 1994; 91:4965.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/26\" class=\"nounderline abstract_t\">Grunewald J, Janson CH, Eklund A, et al. Restricted V alpha 2.3 gene usage by CD4+ T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients correlates with HLA-DR3. Eur J Immunol 1992; 22:129.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/27\" class=\"nounderline abstract_t\">Marrack P, Kappler J. The T cell receptor. Science 1987; 238:1073.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/28\" class=\"nounderline abstract_t\">Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993; 54:99.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/29\" class=\"nounderline abstract_t\">Chen ES, Moller DR. Sarcoidosis--scientific progress and clinical challenges. Nat Rev Rheumatol 2011; 7:457.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/30\" class=\"nounderline abstract_t\">Agostini C, Trentin L, Facco M, et al. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996; 157:910.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/31\" class=\"nounderline abstract_t\">Greene CM, Meachery G, Taggart CC, et al. Role of IL-18 in CD4+ T lymphocyte activation in sarcoidosis. J Immunol 2000; 165:4718.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/32\" class=\"nounderline abstract_t\">Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-gamma production in sarcoid lungs. J Immunol 2001; 166:642.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/33\" class=\"nounderline abstract_t\">Larousserie F, Pflanz S, Coulomb-L'Hermin&eacute; A, et al. Expression of IL-27 in human Th1-associated granulomatous diseases. J Pathol 2004; 202:164.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/34\" class=\"nounderline abstract_t\">Georas SN, Chapman TJ, Crouser ED. Sarcoidosis and T-Helper Cells. Th1, Th17, or Th17.1? Am J Respir Crit Care Med 2016; 193:1198.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/35\" class=\"nounderline abstract_t\">Nishioka Y, Manabe K, Kishi J, et al. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin Exp Immunol 2007; 149:317.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/36\" class=\"nounderline abstract_t\">Wasfi YS, Rose CS, Murphy JR, et al. A new tool to assess sarcoidosis severity. Chest 2006; 129:1234.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/37\" class=\"nounderline abstract_t\">Su R, Nguyen ML, Agarwal MR, et al. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir Res 2013; 14:121.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/38\" class=\"nounderline abstract_t\">Su R, Li MM, Bhakta NR, et al. Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes. Eur Respir J 2014; 44:985.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/39\" class=\"nounderline abstract_t\">Girgis RE, Basha MA, Maliarik M, et al. Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis. Am J Respir Crit Care Med 1995; 152:71.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/40\" class=\"nounderline abstract_t\">Roth C, Huchon GJ, Arnoux A, et al. Bronchoalveolar cells in advanced pulmonary sarcoidosis. Am Rev Respir Dis 1981; 124:9.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/41\" class=\"nounderline abstract_t\">Hunninghake GW, Garrett KC, Richerson HB, et al. Pathogenesis of the granulomatous lung diseases. Am Rev Respir Dis 1984; 130:476.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/42\" class=\"nounderline abstract_t\">Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001; 164:2085.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/43\" class=\"nounderline abstract_t\">Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 2004; 170:1324.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/44\" class=\"nounderline abstract_t\">Iannuzzi MC. Advances in the genetics of sarcoidosis. Proc Am Thorac Soc 2007; 4:457.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/45\" class=\"nounderline abstract_t\">Balmes JR, Abraham JL, Dweik RA, et al. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. Am J Respir Crit Care Med 2014; 190:e34.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/46\" class=\"nounderline abstract_t\">Werfel U, Schneider J, R&ouml;delsperger K, et al. Sarcoid granulomatosis after zirconium exposure with multiple organ involvement. Eur Respir J 1998; 12:750.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/47\" class=\"nounderline abstract_t\">Bartter T, Irwin RS, Abraham JL, et al. Zirconium compound-induced pulmonary fibrosis. Arch Intern Med 1991; 151:1197.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/48\" class=\"nounderline abstract_t\">Cai HR, Cao M, Meng FQ, Wei JY. Pulmonary sarcoid-like granulomatosis induced by aluminum dust: report of a case and literature review. Chin Med J (Engl) 2007; 120:1556.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/49\" class=\"nounderline abstract_t\">Izbicki G, Chavko R, Banauch GI, et al. World Trade Center &quot;sarcoid-like&quot; granulomatous pulmonary disease in New York City Fire Department rescue workers. Chest 2007; 131:1414.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/50\" class=\"nounderline abstract_t\">Jordan HT, Stellman SD, Prezant D, et al. Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster. J Occup Environ Med 2011; 53:966.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/51\" class=\"nounderline abstract_t\">Chen ES, Moller DR. Etiologies of Sarcoidosis. Clin Rev Allergy Immunol 2015; 49:6.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/52\" class=\"nounderline abstract_t\">Mangiapan G, Hance AJ. Mycobacteria and sarcoidosis: an overview and summary of recent molecular biological data. Sarcoidosis 1995; 12:20.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/53\" class=\"nounderline abstract_t\">Mitchell IC, Turk JL, Mitchell DN. Detection of mycobacterial rRNA in sarcoidosis with liquid-phase hybridisation. Lancet 1992; 339:1015.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/54\" class=\"nounderline abstract_t\">Saboor SA, Johnson NM, McFadden J. Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet 1992; 339:1012.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/55\" class=\"nounderline abstract_t\">Bocart D, Lecossier D, De Lassence A, et al. A search for mycobacterial DNA in granulomatous tissues from patients with sarcoidosis using the polymerase chain reaction. Am Rev Respir Dis 1992; 145:1142.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/56\" class=\"nounderline abstract_t\">Richter E, Greinert U, Kirsten D, et al. Assessment of mycobacterial DNA in cells and tissues of mycobacterial and sarcoid lesions. Am J Respir Crit Care Med 1996; 153:375.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/57\" class=\"nounderline abstract_t\">Vokurka M, Lecossier D, du Bois RM, et al. Absence of DNA from mycobacteria of the M. tuberculosis complex in sarcoidosis. Am J Respir Crit Care Med 1997; 156:1000.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/58\" class=\"nounderline abstract_t\">Wilsher ML, Menzies RE, Croxson MC. Mycobacterium tuberculosis DNA in tissues affected by sarcoidosis. Thorax 1998; 53:871.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/59\" class=\"nounderline abstract_t\">Ishige I, Usui Y, Takemura T, Eishi Y. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 1999; 354:120.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/60\" class=\"nounderline abstract_t\">Almenoff PL, Johnson A, Lesser M, Mattman LH. Growth of acid fast L forms from the blood of patients with sarcoidosis. Thorax 1996; 51:530.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/61\" class=\"nounderline abstract_t\">Brown ST, Brett I, Almenoff PL, et al. Recovery of cell wall-deficient organisms from blood does not distinguish between patients with sarcoidosis and control subjects. Chest 2003; 123:413.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/62\" class=\"nounderline abstract_t\">Planck A, Eklund A, Grunewald J, Vene S. No serological evidence of Rickettsia helvetica infection in Scandinavian sarcoidosis patients. Eur Respir J 2004; 24:811.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/63\" class=\"nounderline abstract_t\">Rotsinger JE, Celada LJ, Polosukhin VV, et al. Molecular Analysis of Sarcoidosis Granulomas Reveals Antimicrobial Targets. Am J Respir Cell Mol Biol 2016; 55:128.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/64\" class=\"nounderline abstract_t\">Fang C, Huang H, Xu Z. Immunological Evidence for the Role of Mycobacteria in Sarcoidosis: A Meta-Analysis. PLoS One 2016; 11:e0154716.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/65\" class=\"nounderline abstract_t\">Celada LJ, Hawkins C, Drake WP. The Etiologic Role of Infectious Antigens in Sarcoidosis Pathogenesis. Clin Chest Med 2015; 36:561.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/66\" class=\"nounderline abstract_t\">de Brouwer B, Veltkamp M, Wauters CA, et al. Propionibacterium acnes isolated from lymph nodes of patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32:271.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/67\" class=\"nounderline abstract_t\">Burke WM, Keogh A, Maloney PJ, et al. Transmission of sarcoidosis via cardiac transplantation. Lancet 1990; 336:1579.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/68\" class=\"nounderline abstract_t\">Heyll A, Meckenstock G, Aul C, et al. Possible transmission of sarcoidosis via allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14:161.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/69\" class=\"nounderline abstract_t\">Bhagat R, Rizzieri DA, Vredenburgh JJ, et al. Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence? Chest 2004; 126:642.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/70\" class=\"nounderline abstract_t\">Slebos DJ, Verschuuren EA, Ko&euml;ter GH, et al. Bronchoalveolar lavage in a patient with recurrence of sarcoidosis after lung transplantation. J Heart Lung Transplant 2004; 23:1010.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/71\" class=\"nounderline abstract_t\">Ionescu DN, Hunt JL, Lomago D, Yousem SA. Recurrent sarcoidosis in lung transplant allografts: granulomas are of recipient origin. Diagn Mol Pathol 2005; 14:140.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/72\" class=\"nounderline abstract_t\">Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005; 201:755.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/73\" class=\"nounderline abstract_t\">Chen ES, Wahlstr&ouml;m J, Song Z, et al. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008; 181:8784.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/74\" class=\"nounderline abstract_t\">Nishiwaki T, Yoneyama H, Eishi Y, et al. Indigenous pulmonary Propionibacterium acnes primes the host in the development of sarcoid-like pulmonary granulomatosis in mice. Am J Pathol 2004; 165:631.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/75\" class=\"nounderline abstract_t\">Di Alberti L, Piattelli A, Artese L, et al. Human herpesvirus 8 variants in sarcoid tissues. Lancet 1997; 350:1655.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/76\" class=\"nounderline abstract_t\">B&eacute;lec L, Mohamed AS, Lechapt-Zalcman E, et al. Lack of HHV-8 DNA sequences in sarcoid tissues of French patients. Chest 1998; 114:948.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/77\" class=\"nounderline abstract_t\">Maeda H, Niimi T, Sato S, et al. Human herpesvirus 8 is not associated with sarcoidosis in Japanese patients. Chest 2000; 118:923.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/78\" class=\"nounderline abstract_t\">SILTZBACH LE. The Kveim test in sarcoidosis. A study of 750 patients. JAMA 1961; 178:476.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/79\" class=\"nounderline abstract_t\">Eberhardt C, Thillai M, Parker R, et al. Proteomic Analysis of Kveim Reagent Identifies Targets of Cellular Immunity in Sarcoidosis. PLoS One 2017; 12:e0170285.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/80\" class=\"nounderline abstract_t\">Grunewald J, Kaiser Y, Ostadkarampour M, et al. T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis. Eur Respir J 2016; 47:898.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/81\" class=\"nounderline abstract_t\">Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med 2010; 181:360.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/82\" class=\"nounderline abstract_t\">Patterson KC, Chen ES. The Pathogenesis of Pulmonary Sarcoidosis and Implications for Treatment. Chest 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/83\" class=\"nounderline abstract_t\">Huho A, Foulke L, Jennings T, et al. The role of serum amyloid A staining of granulomatous tissues for the diagnosis of sarcoidosis. Respir Med 2017; 126:1.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/84\" class=\"nounderline abstract_t\">Rybicki BA, Harrington D, Major M, et al. Heterogeneity of familial risk in sarcoidosis. Genet Epidemiol 1996; 13:23.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/85\" class=\"nounderline abstract_t\">Brennan NJ, Crean P, Long JP, Fitzgerald MX. High prevalence of familial sarcoidosis in an Irish population. Thorax 1984; 39:14.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/86\" class=\"nounderline abstract_t\">Rybicki BA, Kirkey KL, Major M, et al. Familial risk ratio of sarcoidosis in African-American sibs and parents. Am J Epidemiol 2001; 153:188.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/87\" class=\"nounderline abstract_t\">Sverrild A, Backer V, Kyvik KO, et al. Heredity in sarcoidosis: a registry-based twin study. Thorax 2008; 63:894.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/88\" class=\"nounderline abstract_t\">Fischer A, Rybicki BA. Granuloma genes in sarcoidosis: what is new? Curr Opin Pulm Med 2015; 21:510.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/89\" class=\"nounderline abstract_t\">M&uuml;ller-Quernheim J, Sch&uuml;rmann M, Hofmann S, et al. Genetics of sarcoidosis. Clin Chest Med 2008; 29:391.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/90\" class=\"nounderline abstract_t\">Rybicki BA, Maliarik MJ, Poisson LM, et al. The major histocompatibility complex gene region and sarcoidosis susceptibility in African Americans. Am J Respir Crit Care Med 2003; 167:444.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/91\" class=\"nounderline abstract_t\">Ina Y, Takada K, Yamamoto M, et al. HLA and sarcoidosis in the Japanese. Chest 1989; 95:1257.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/92\" class=\"nounderline abstract_t\">Odum N, Milman N, Jakobsen BK, et al. HLA class II (DR, DQ, DP) in patients with sarcoidosis: evidence of an increased frequency of DRw6. Exp Clin Immunogenet 1991; 8:227.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/93\" class=\"nounderline abstract_t\">Martinetti M, Tinelli C, Kolek V, et al. &quot;The sarcoidosis map&quot;: a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995; 152:557.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/94\" class=\"nounderline abstract_t\">Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003; 73:720.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/95\" class=\"nounderline abstract_t\">Mehra NK, Bovornkitti S. HLA and sarcoidosis. Sarcoidosis 1988; 5:87.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/96\" class=\"nounderline abstract_t\">Berlin M, Fogdell-Hahn A, Olerup O, et al. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997; 156:1601.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/97\" class=\"nounderline abstract_t\">Grunewald J. Genetics of sarcoidosis. Curr Opin Pulm Med 2008; 14:434.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/98\" class=\"nounderline abstract_t\">Pabst S, Karpushova A, Diaz-Lacava A, et al. VEGF gene haplotypes are associated with sarcoidosis. Chest 2010; 137:156.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/99\" class=\"nounderline abstract_t\">Fischer A, Nothnagel M, Sch&uuml;rmann M, et al. A genome-wide linkage analysis in 181 German sarcoidosis families using clustered biallelic markers. Chest 2010; 138:151.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/100\" class=\"nounderline abstract_t\">Fischer A, Schmid B, Ellinghaus D, et al. A novel sarcoidosis risk locus for Europeans on chromosome 11q13.1. Am J Respir Crit Care Med 2012; 186:877.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/101\" class=\"nounderline abstract_t\">Hofmann S, Fischer A, Nothnagel M, et al. Genome-wide association analysis reveals 12q13.3-q14.1 as new risk locus for sarcoidosis. Eur Respir J 2013; 41:888.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/102\" class=\"nounderline abstract_t\">Valentonyte R, Hampe J, Huse K, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005; 37:357.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/103\" class=\"nounderline abstract_t\">Hofmann S, Franke A, Fischer A, et al. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nat Genet 2008; 40:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/104\" class=\"nounderline abstract_t\">Li Y, Pabst S, Kubisch C, et al. First independent replication study confirms the strong genetic association of ANXA11 with sarcoidosis. Thorax 2010; 65:939.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/105\" class=\"nounderline abstract_t\">Maliarik MJ, Rybicki BA, Malvitz E, et al. Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med 1998; 158:1566.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/106\" class=\"nounderline abstract_t\">Pietinalho A, Furuya K, Yamaguchi E, et al. The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J 1999; 13:723.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/107\" class=\"nounderline abstract_t\">Crouser ED, Culver DA, Knox KS, et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 2009; 179:929.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/108\" class=\"nounderline abstract_t\">Lockstone HE, Sanderson S, Kulakova N, et al. Gene set analysis of lung samples provides insight into pathogenesis of progressive, fibrotic pulmonary sarcoidosis. Am J Respir Crit Care Med 2010; 181:1367.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/109\" class=\"nounderline abstract_t\">Zhou T, Zhang W, Sweiss NJ, et al. Peripheral blood gene expression as a novel genomic biomarker in complicated sarcoidosis. PLoS One 2012; 7:e44818.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/110\" class=\"nounderline abstract_t\">Verbsky JW, Routes JM. Sarcoidosis and common variable immunodeficiency: similarities and differences. Semin Respir Crit Care Med 2014; 35:330.</a></li><li><a href=\"https://www.uptodate.com/contents/pathology-and-pathogenesis-of-sarcoidosis/abstract/111\" class=\"nounderline abstract_t\">Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin Immunol 2010; 134:97.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4365 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H16\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOLOGY</a></li><li><a href=\"#H452678738\" id=\"outline-link-H452678738\">IMMUNOPATHOGENESIS</a><ul><li><a href=\"#H1205830726\" id=\"outline-link-H1205830726\">Macrophages and dendritic cells</a></li><li><a href=\"#H379141950\" id=\"outline-link-H379141950\">T lymphocytes</a><ul><li><a href=\"#H3645136627\" id=\"outline-link-H3645136627\">- T helper cells</a></li><li><a href=\"#H690504389\" id=\"outline-link-H690504389\">- T regulatory cells</a></li></ul></li><li><a href=\"#H3196799771\" id=\"outline-link-H3196799771\">T cell receptor</a></li><li><a href=\"#H1983033123\" id=\"outline-link-H1983033123\">Cytokines</a></li></ul></li><li><a href=\"#H3\" id=\"outline-link-H3\">POSSIBLE ETIOLOGIC AGENTS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Occupational and environmental exposures</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Infectious agents</a></li><li><a href=\"#H2269876926\" id=\"outline-link-H2269876926\">Kveim-Siltzbach reagent</a></li><li><a href=\"#H2219860226\" id=\"outline-link-H2219860226\">Potential role for vimentin</a></li><li><a href=\"#H2358848511\" id=\"outline-link-H2358848511\">Serum amyloid A</a></li></ul></li><li><a href=\"#H575707723\" id=\"outline-link-H575707723\">GENETIC PREDISPOSITION</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Major histocompatibility complex</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Other genes</a></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">OTHER ASSOCIATIONS</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Granulomatous and lymphocytic interstitial lung disease</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H15\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/4365|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/53512\" class=\"graphic graphic_figure\">- HLA TCR complex</a></li><li><a href=\"image.htm?imageKey=PULM/53335\" class=\"graphic graphic_figure\">- Arrangement of T cell receptor</a></li><li><a href=\"image.htm?imageKey=ALLRG/78712\" class=\"graphic graphic_figure\">- T cell regulation by cytokines</a></li></ul></li><li><div id=\"PULM/4365|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/115232\" class=\"graphic graphic_picture\">- Noncaseating granulomas in sarcoidosis</a></li><li><a href=\"image.htm?imageKey=PULM/83308\" class=\"graphic graphic_picture\">- Sarcoid granuloma with an asteroid body</a></li><li><a href=\"image.htm?imageKey=PULM/83306\" class=\"graphic graphic_picture\">- Sarcoid granuloma with Schaumann body</a></li><li><a href=\"image.htm?imageKey=PULM/83307\" class=\"graphic graphic_picture\">- Sarcoid granuloma with calcium oxalate crystal</a></li></ul></li><li><div id=\"PULM/4365|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/76046\" class=\"graphic graphic_table\">- Sarcoid organ involvement</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antigen-presenting-cells\" class=\"medical medical_review\">Antigen-presenting cells</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-cardiac-sarcoidosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of cardiac sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of pulmonary sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-manifestations-of-sarcoidosis\" class=\"medical medical_review\">Cutaneous manifestations of sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extrapulmonary-manifestations-of-sarcoidosis\" class=\"medical medical_review\">Extrapulmonary manifestations of sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gastrointestinal-and-hepatic-sarcoidosis\" class=\"medical medical_review\">Gastrointestinal and hepatic sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=invasive-cutibacterium-formerly-propionibacterium-infections\" class=\"medical medical_review\">Invasive Cutibacterium (formerly Propionibacterium) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-cutaneous-sarcoidosis\" class=\"medical medical_review\">Management of cutaneous sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurologic-sarcoidosis\" class=\"medical medical_review\">Neurologic sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=normal-b-and-t-lymphocyte-development\" class=\"medical medical_review\">Normal B and T lymphocyte development</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sarcoidosis-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Sarcoidosis (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=sarcoidosis-the-basics\" class=\"medical medical_basics\">Patient education: Sarcoidosis (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-complications-of-primary-immunodeficiencies\" class=\"medical medical_review\">Pulmonary complications of primary immunodeficiencies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=renal-disease-in-sarcoidosis\" class=\"medical medical_review\">Renal disease in sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-cytokines-in-the-immune-system\" class=\"medical medical_review\">Role of cytokines in the immune system</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=t-helper-subsets-differentiation-and-role-in-disease\" class=\"medical medical_review\">T helper subsets: Differentiation and role in disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-sarcoidosis-initial-therapy-with-glucocorticoids\" class=\"medical medical_review\">Treatment of pulmonary sarcoidosis: Initial therapy with glucocorticoids</a></li></ul></div></div>","javascript":null}